News | Prostate Cancer | February 18, 2016

Weill Cornell Partners for Non-Invasive Prostate Cancer Detection

Cancer institute will investigate use of Senior Scientific’s magnetic relaxometry technology for detection and diagnosis

Weill Cornell Medicine, Senior Scientific, magnetix relaxometry, MRX technology, prostate cancer detection

February 18, 2016 — Manhattan Scientifics Inc. announced its wholly-owned subsidiary Senior Scientific LLC, which is developing a platform for the early detection of cancer and other human diseases, has established a research collaboration with Weill Cornell Medicine. For the alliance, the company will bring its magnetic relaxometry technology to Weill Cornell Medicine, where scientists will investigate the use of molecularly targeted nanoparticles to non-invasively detect and diagnose prostate cancers.

“We have extensive experience in targeting radionuclides to cancer for imaging and therapy using antibodies and small molecules,” said John Babich, Ph.D., professor of radiopharmaceutical sciences in radiology at Weill Cornell Medicine. “This collaboration enables us to leverage our expertise in prostate cancer targeting to explore Senior Scientific’s non-radioactive magnetic nanoparticle platform for early detection of cancer.”

Gary Dorfman, M.D., vice chairman for research at the Weill Cornell Medicine Department of Radiology and professor of radiology, added, “The MRX technology may have advantages for patient care compared to PET [positron emission tomography, CT [computed tomography or MRI [magnetic resonance imaging] methods, and we are looking forward to working with Senior Scientific to investigate the diagnostic applications of this technology for patients.”

On Jan. 13, 2016, the company announced it would be working with the University of Michigan Medical School on a breast cancer program, adding to its existing ovarian cancer program with the MD Anderson Cancer Center. With the addition of Weill Cornell Medicine focusing on prostate cancer, the company has engaged with three pre-eminent U.S. cancer institutes to develop commercial applications of its magnetic relaxometry platform. Each of the three institutions will have the MRX technology on-site, enabling them to undertake the pre-clinical animal model studies necessary in anticipation of first-in-human testing.

For more information: www.seniorscientific.com

Related Content

Toshiba Showcases MRI Workflow Enhancements at RSNA 2017
News | Magnetic Resonance Imaging (MRI) | September 21, 2017
September 21, 2017 — Toshiba Medical will highlight its latest...
ProCure Proton Therapy Center New Jersey Celebrates Five-Year Cancer-Free Milestone for Prostate Cancer Patients
News | Proton Therapy | September 20, 2017
ProCure Proton Therapy Center in Somerset, N.J., recently celebrated the five-year cancer-free milestone for the first...
News | Business | September 19, 2017
September 19, 2017 — Invicro LLC, a provider of imaging services and software for research and drug development, anno
ScImage and Invia Partnership Announced
News | PACS | September 19, 2017
ScImage Inc. and Invia Imaging Solutions recently announced formation of a joint partnership at the American Society of...
Siemens Healthineers to Showcase Magentom Vida MRI at RSNA 2017
Technology | Magnetic Resonance Imaging (MRI) | September 18, 2017
September 18, 2017 — Siemens Healthineers announced it will display the new Magnetom Vida 3T...
Toshiba Highlights Latest CT Advancements at RSNA 2017
News | Computed Tomography (CT) | September 18, 2017
Toshiba Medical announced that it will display several new enhancements to its existing computed tomography (CT)...
Philips Launches CardioMD IV Cardiac SPECT Solution at ASNC 2017
Technology | SPECT Imaging | September 15, 2017
September 15, 2017 — Philips highlighted its newest solution for...
Double Targeting Ligands to Identify and Treat Prostate Cancer

The mice were imaged with small-animal PET/CT using 124I-RPS-027 (7.4 MBq [200 μCi]). Credit: JM Kelly et al., Department of Radiology, Weill Cornell Medicine, New York, NY

News | Prostate Cancer | September 14, 2017
Researchers have demonstrated a new, effective way to precisely identify and localize prostate cancer tumors while...
Blue Earth Diagnostics Announcing Results of FALCON PET/CT Trial at ASTRO 2017
News | PET-CT | September 13, 2017
September 13, 2017 — Blue Earth Diagnostics announced the upcoming oral presentation of initial results from the FALC
Overlay Init